A detailed history of Rise Advisors, LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Rise Advisors, LLC holds 30 shares of NVCR stock, worth $512. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30
Previous 30 -0.0%
Holding current value
$512
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 10, 2023

SELL
$16.15 - $42.35 $403 - $1,058
-25 Reduced 45.45%
30 $0
Q3 2022

Oct 11, 2022

SELL
$67.99 - $89.57 $3,399 - $4,478
-50 Reduced 47.62%
55 $4,000
Q1 2022

Apr 22, 2022

BUY
$60.15 - $84.52 $1,804 - $2,535
30 Added 40.0%
105 $9,000
Q4 2021

Feb 24, 2022

BUY
$75.08 - $121.99 $5,631 - $9,149
75 New
75 $5.63 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.79B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Rise Advisors, LLC Portfolio

Follow Rise Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rise Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rise Advisors, LLC with notifications on news.